GWSA
GALT icon

Global Wealth Strategies & Associates’s Galectin Therapeutics GALT Stock Holding History

Global Wealth Strategies & Associates’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,000
Closed -$1.13K – 369
2022
Q4 		$1.13K Buy
+1,000
New +$1.33K ﹤0.01% 293

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
AWS
Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

Global Wealth Strategies & Associates's GALT Position: Q1 2023 in Review

Global Wealth Strategies & Associates sold out of Galectin Therapeutics (GALT) in Q1 2023, closing a stake of 1,000 shares — an estimated $1.13K sold.

Global Wealth Strategies & Associates first reported a position in GALT in Q4 2022 and held it in 1 quarter. The position peaked at $1.13K in Q4 2022. 60 funds tracked by Wall St. Rank hold GALT as of Q1 2023.

  • Global Wealth Strategies & Associates reported no remaining Galectin Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Global Wealth Strategies & Associates sold 1,000 Galectin Therapeutics shares in Q1 2023, an estimated $1.13K.
  • Global Wealth Strategies & Associates first reported a position in Galectin Therapeutics in Q4 2022 and held it in 1 quarter.
  • Global Wealth Strategies & Associates's Galectin Therapeutics position peaked at $1.13K in Q4 2022.
  • 60 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2023.

Based on Global Wealth Strategies & Associates's 13F filing for Q1 2023, filed 3 Apr 2023.